Use of crizotinib as neoadjuvant therapy for non‐small cell lung cancers patient with ROS1 rearrangement: A case report

Crizotinib showed significant antitumor effect in patients with advanced ROS1‐rearranged non‐small cell lung cancers (NSCLC). Most recently, many studies have explored the feasibility and efficacy of target therapy for perioperative application in NSCLC. Here, we describe a female patient who was di...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Shikang, Zhu, Shuai, Lei, Xi, Xu, Dongbo, Shi, Tao, Chen, Qiusong, Ren, Fan, Chen, Gang, Huang, Dingzhi, Xu, Song
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2021
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520795/
https://www.ncbi.nlm.nih.gov/pubmed/34405544
http://dx.doi.org/10.1111/1759-7714.14112

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520795/
https://www.ncbi.nlm.nih.gov/pubmed/34405544
http://dx.doi.org/10.1111/1759-7714.14112

Ejemplares similares